Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 8—August 2024
Dispatch

Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody

Author affiliation: The University of Tokyo, Tokyo, Japan

Cite This Article

Abstract

A patient in Japan with HIV began antiretroviral therapy because of acute hepatitis B virus (HBV) 15 years ago, with low hepatitis B surface antibody, and experienced breakthrough HBV reactivation 4 months after switching from bictegravir/emtricitabine/tenofovir alafenamide to cabotegravir/rilpivirine. An immune escape mutation, E164V, was identified in the isolated HBV DNA.

The 2013 guidelines outlined by the Centers for Disease Control and Prevention indicate in cases where hepatitis B surface antibody (anti-HBs) titers fall below the cut off value of 10.0 mIU/mL, administration of booster vaccinations is generally not required, barring certain exceptions, such as immunocompromised persons (1). This recommendation is based on the understanding that exposure to hepatitis B virus (HBV) typically triggers B lymphocytes, culminating in the production of adequate antibody levels within a short timeframe. However, the effectiveness of this antibody response following HBV exposure depends on the persons immune status. The primary goal in managing chronic hepatitis B is to achieve an undetectable hepatitis B surface antigen (HBsAg) level. Cases where seroconversion from HBsAg to anti-HBs occurs is considered a functional cure, although, the risk for de novo reactivation persists and is not eliminated (2).

Isolated hepatitis B core antibody (anti-HBc) positivity, defined as antigen negative, anti-HBs negative, and anti-HBc positive, is considered a risk factor for occult HBV infection (3) and de novo HBV reactivation (4), indicating 2 distinct pathogenic pathways. The first scenario involves HBsAg negativity resulting from treatment or spontaneous resolution, without subsequent seroconversion to anti-HBs. The second scenario occurs when anti-HBs levels decline below the threshold of detection after initially testing positive. When anti-HBs levels decline, exposure-induced boosting is expected to provide a preventive effect.

We describe the case of a patient with HIV whose anti-HBs titers declined below the threshold of detection after an initial confirmation of anti-HBs positivity. The patient’s medications were changed from bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) to cabotegravir/rilpivirine (CAB/RPV). His HBsAg positivity recurred, and he reverted to being an HBV carrier.

Ethics approval was granted by the ethics board of the Institute of Medical Science, University of Tokyo (approval no. 2022-48-1128). The patient gave consent for publication in accordance with the policies of Emerging Infectious Diseases and the International Committee of Medical Journal Editors.

The Case

A 52-year-old man with HIV had contracted an acute HBV infection 15 years earlier. Antiretroviral therapy (ART) consisting of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) and lopinavir/ritonavir (LPV/RTV) was initiated at the time, and the acute hepatitis rapidly improved. The patient’s liver enzymes normalized 2 months after beginning ART, and he tested negative for HBV DNA and HBsAg 4 months after beginning ART (Table 1). Anti-HBs titers were detected at 2.03 IU/mL 9 months after beginning ART, and it was believed that his acute hepatitis B did not transition into a chronic HBV infection. His anti-HBs titers were again detected at 18.6 IU/mL 6 years after the initial diagnosis of the acute HBV infection. There was no reactivation of HBV while on stable ART containing TDF/FTC or TAF/FTC. Two years after the confirmation of seroconversion, his anti-HBs levels decreased below the cutoff value but remained around 8.0 mIU/mL. He tested positive for anti-HBc.

After 14 years of ART, the patient expressed a preference to change to a long-acting injectable ART. We considered 3 additional factors before making this medication change: the patient did not become an HBV carrier after his acute hepatitis B diagnosis, his HBsAg and his HBV DNA had remained undetectable for >10 years, and his anti-HBs had declined only after initial positive confirmation. His hepatitis B core-related antigen, which is shown to remain positive longer than HBsAg and HBV DNA in acute hepatitis B infections (5,6), was negative. After a 1-month lead-in with oral CAB/RPV, his ART was changed to an injectable CAB/RPV.

The patient’s liver enzyme levels increased to alanine aminotransferase (ALT) 103 U/L (reference range 4–44 U/L) 4 months after switching to CAB/RPV. Both his HBsAg and HBV DNA tested positive again, while the level of anti-HBs decreased to nearly zero (Table 2). The probability of reinfection with a novel HBV strain was considered low because his sexual partner was on ART containing tenofovir during this period and the patient denied any other potential exposures. The patient’s CD4 count was 512 cells/μL, indicating sufficient immune function. The patient’s liver enzymes returned to within reference ranges 4 months later, whereas the HBsAg and HBV DNA remained elevated. The patient’s ART regimen was switched to B/F/TAF 14 months after the change to CAB/RPV because of concerns of a concurrent chronic HBV infection.

We cloned 2 full-length HBV isolates and determined the genome sequences from serum samples obtained at 2 intervals: the first after 4 months of treatment with CAB/RPV, coinciding with the re-positivity of HBsAg, and the second 14 months after treatment with CAB/RPV (Appendix). Our genomic analysis revealed identical clones of genotype A2, and we observed no increases in mutations after reactivation (Table 3). Of note, E164V was identified within the S region and is recognized as a vaccine-escape mutation (Appendix Figure) (7). No drug resistance–associated mutations were observed in the polymerase region.

There are multiple explanations for the re-emergence of HBsAg in this case. The mostly likely explanation is our patient did not attain a functional cure of HBV. The reduction in HBsAg might have been because of ART containing TDF/FTC or TAF/FTC instead of acquired immunity against HBV, implying that anti-HBs levels were inadequate. After switching to CAB/RPV, the drugs no longer suppressed HBV. The exposure to reactivated HBV did not adequately boost the anti-HBs levels, which lead to breakthrough reactivation. Another potential explanation is a de novo reactivation of HBV independent of switching to CAB/RPV. However, we were unable to find documented cases of de novo HBV reactivation among persons on stable ART or with a stable immune status. Furthermore, whereas de novo HBV reactivation typically leads to severe hepatitis (8), our patient remained asymptomatic, with only a marginal elevation in transaminase levels.

E164V in the S region is known as a vaccine-escape mutation and is frequently identified in patients with occult HBV infection or de novo HBV reactivation (9,10). Cases of breakthrough infection are extremely rare worldwide, and it is not clear whether a single mutation is responsible for immune escape. In patients with occult HBV infection, escape mutations other than E164V are typically detected alongside other mutations (10,11).

HBV reactivation has been reported in patients with low CD4 counts (12,13). Cases have also been reported of HBV DNA detection at very low levels with negative HBsAg after switching to ART regimens without anti-HBV drugs (14). Our patient had a sufficient CD4 count for immunity and a history of anti-HBc and anti-HBs positivity, and still we found his HBV reactivated with re-emergence of HBsAg. We expect our patient will undergo the seroconversion of HBsAg again with ART containing F/TAF. Nonetheless, ART without tenofovir or lamivudine is not an option for this patient in the future.

Conclusions

Below the cutoff value, the preventive effect of anti-HBs may not be sufficient to prevent reactivation. Vaccination may be beneficial for patients with isolated anti-HBc positivity, even if their anti-HBs levels have declined since their initial anti-HBs positivity was confirmed (15). For many years, ART containing tenofovir or lamivudine has been widely used worldwide; however, providers are increasingly using ART regimens that do not include anti-HBV drug. Healthcare providers must consider the potential scenario where the detection of anti-HBs might be a consequence of HBV suppression through ART containing anti-HBV drugs, and not indicative of a functional cure. Switching to ART regimens without anti-HBV drugs should be approached with caution.

Nucleotide sequence data are registered in the GenBank database (accession nos. LC789983 and LC789984).

Author contributions: project design, E.A.; manuscript drafting, E.A.; clinical course review, E.A., M.S., and H.Y.; manuscript revision, E.A., M.S., and H.Y.; patient management, E.A., A.O., Y.K., M.S., M.K., and H.Y.; genomic analysis, A.S., K.A., and K.T. All authors approved the final manuscript.

Dr. Adachi is an infectious disease physician with the University of Tokyo and specializes in HIV/AIDS research.

Top

References

  1. Schillie  S, Murphy  TV, Sawyer  M, Ly  K, Hughes  E, Jiles  R, et al.; Centers for Disease Control and Prevention (CDC). CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR Recomm Rep. 2013;62(RR-10):119.PubMedGoogle Scholar
  2. Honda  T, Yamada  N, Murayama  A, Shiina  M, Aly  HH, Kato  A, et al. Amino acid polymorphism in hepatitis B virus associated with functional cure. Cell Mol Gastroenterol Hepatol. 2021;12:158398. DOIPubMedGoogle Scholar
  3. Firnhaber  C, Viana  R, Reyneke  A, Schultze  D, Malope  B, Maskew  M, et al. Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis. 2009;13:48892. DOIPubMedGoogle Scholar
  4. Dickson  RC, Everhart  JE, Lake  JR, Wei  Y, Seaberg  EC, Wiesner  RH, et al.; The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology. 1997;113:166874. DOIPubMedGoogle Scholar
  5. Kuhns  MC, Holzmayer  V, McNamara  AL, Anderson  M, Cloherty  GA. Hepatitis B seroconversion revisited: new insights into the natural history of acute hepatitis B virus (HBV) infection from quantitative and highly sensitive assays and novel biomarkers. Virol J. 2021;18:235. DOIPubMedGoogle Scholar
  6. Wong  DK, Tanaka  Y, Lai  CL, Mizokami  M, Fung  J, Yuen  MF. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol. 2007;45:39427. DOIPubMedGoogle Scholar
  7. Ma  Q, Wang  Y. Comprehensive analysis of the prevalence of hepatitis B virus escape mutations in the major hydrophilic region of surface antigen. J Med Virol. 2012;84:198206. DOIPubMedGoogle Scholar
  8. Lubel  JS, Angus  PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol. 2010;25:86471. DOIPubMedGoogle Scholar
  9. Ye  Q, Shang  SQ, Li  W. A new vaccine escape mutant of hepatitis B virus causes occult infection. Hum Vaccin Immunother. 2015;11:40710. DOIPubMedGoogle Scholar
  10. Anastasiou  OE, Almpani  F, Herrmann  A, Gerken  G, Ditschkowski  M, Ciesek  S. HBV reactivation in allogeneic stem cell transplant recipients: Risk factors, outcome, and role of hepatitis B virus mutations. Hepatol Commun. 2017;1:101423. DOIPubMedGoogle Scholar
  11. Lazarevic  I, Banko  A, Miljanovic  D, Cupic  M. Immune-escape hepatitis B virus mutations associated with viral reactivation upon immunosuppression. Viruses. 2019;11:778. DOIPubMedGoogle Scholar
  12. Mican  R, Busca Arenzana  C, Vasquez  J, Daroca  G, Perez-Valero  I, Martin-Carbonero  L. Hepatitis B reactivation after tenofovir withdrawal in an HIV-infected patient with history of cured hepatitis B virus infection and poor immunological status. AIDS. 2021;35:17078. DOIPubMedGoogle Scholar
  13. Vasishta  S, Dieterich  D, Mullen  M, Aberg  J. Brief Report: Hepatitis B infection or reactivation after switch to 2-drug antiretroviral therapy: a case series, literature review, and management discussion. J Acquir Immune Defic Syndr. 2023;94:1604. DOIPubMedGoogle Scholar
  14. Welford  E, Yin  J, Hill  L, Wooten  D. A case series of low-level HBV viremia after switching to long-acting injectable cabotegravir/rilpivirine in patients with HIV, hepatitis B core antibody positivity, and hepatitis B surface antigen negativity. In: Abstracts of IDweek 2022; Washington, DC, USA; 2022 Oct 19–23. Abstract 1583. Arlington (VA): Infectious Diseases Society of America; 2022.
  15. Piroth  L, Launay  O, Michel  ML, Bourredjem  A, Miailhes  P, Ajana  F, et al.; ANRS HB EP03 CISOVAC Study Group. ANRS HB EP03 CISOVAC Study Group. Vaccination against hepatitis B virus (HBV) in HIV-1–infected patients with isolated anti-HBV core antibody: the ANRS HB EP03 CISOVAC prospective study. J Infect Dis. 2016;213:173542. DOIPubMedGoogle Scholar

Top

Tables

Top

Cite This Article

DOI: 10.3201/eid3008.240019

Original Publication Date: July 19, 2024

1These first authors contributed equally to this article.

Table of Contents – Volume 30, Number 8—August 2024

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Eisuke Adachi, IMSUT Hospital, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan

Send To

10000 character(s) remaining.

Top

Page created: June 28, 2024
Page updated: July 21, 2024
Page reviewed: July 21, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external